Clinical Trials
35 trialsLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
LaNova Medicines Limited
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STORM Therapeutics LTD
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
TRANSPARENT
Coherus Oncology, Inc.
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Elpiscience Biopharma, Ltd.
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Limited
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase â… /â…¡ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
RemeGen Co., Ltd.
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
LaNova Medicines Limited
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Abbisko Therapeutics Co, Ltd
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.